Relapse risk and relapse-free survival from end of therapy. Relapse risk (A) and relapse-free survival (B) from end of therapy for patients with no documented residual disease (RD) during therapy (no RD), with RD at the end of therapy (RD positive), and without RD at the end of therapy with previously documented RD.